{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:30:09Z","timestamp":1778301009200,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40262-016-0387-2","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T10:37:05Z","timestamp":1460716625000},"page":"1103-1113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cellular Uptake of Glucocerebrosidase in Gaucher Patients Receiving Enzyme Replacement Treatment"],"prefix":"10.1007","volume":"55","author":[{"given":"Elena","family":"Gras-Colomer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Amparo","family":"Mart\u00ednez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Moya-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Fernandez-Zarzoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Merino-Sanjuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Climente-Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"key":"387_CR1","first-page":"377","volume":"21","author":"GA Grabowski","year":"1993","unstructured":"Grabowski GA. Gaucher disease: enzymology, genetics, and treatment. Adv Hum Genet. 1993;21:377\u2013441.","journal-title":"Adv Hum Genet"},{"issue":"4 Suppl 5","key":"387_CR2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4 Suppl 5):4\u201314.","journal-title":"Semin Hematol"},{"key":"387_CR3","first-page":"3635","volume-title":"The metabolic and molecular bases of inherited disease","author":"E Beutler","year":"2011","unstructured":"Beutler E, Grabowski GA. Gaucher disease. In: Scriver C, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. Vol. III. New York: McGraw-Hill; 2011. p. 3635\u20133668.","edition":"8"},{"issue":"3","key":"387_CR4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/A:1010514614570","volume":"24","author":"A Vellodi","year":"2001","unstructured":"Vellodi A, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis. 2001;24(3):319\u201327.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"387_CR5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/bcmd.1995.0012","volume":"21","author":"E Beutler","year":"1995","unstructured":"Beutler E, et al. The clinical course of treated and untreated Gaucher disease: a study of 45 patients. Blood Cells Mol Dis. 1995;21(2):86\u2013108.","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"387_CR6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0950-3536(97)80031-5","volume":"10","author":"RO Brady","year":"1997","unstructured":"Brady RO. Gaucher\u2019s disease: past, present and future. Baillieres Clin Haematol. 1997;10(4):621\u201334.","journal-title":"Baillieres Clin Haematol"},{"issue":"23\u201324","key":"387_CR7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10354-010-0814-1","volume":"160","author":"OA Bodamer","year":"2010","unstructured":"Bodamer OA, Hung C. Laboratory and genetic evaluation of Gaucher disease. Wien Med Wochenschr. 2010;160(23\u201324):600\u20134.","journal-title":"Wien Med Wochenschr"},{"issue":"7647","key":"387_CR8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(70)91646-6","volume":"1","author":"E Beutler","year":"1970","unstructured":"Beutler E, Kuhl W. Detection of the defect of Gaucher\u2019s disease and its carrier state in peripheral-blood leucocytes. Lancet. 1970;1(7647):612\u20133.","journal-title":"Lancet"},{"issue":"5","key":"387_CR9","first-page":"747","volume":"76","author":"E Beutler","year":"1970","unstructured":"Beutler E, Kuhl W. The diagnosis of the adult type of Gaucher\u2019s disease and its carrier state by demonstration of deficiency of beta-glucosidase activity in peripheral blood leukocytes. J Lab Clin Med. 1970;76(5):747\u201355.","journal-title":"J Lab Clin Med"},{"key":"387_CR10","volume-title":"Vpriv (velaglucerase): European public assessment report","author":"Shire Pharmaceuticals","year":"2010","unstructured":"Pharmaceuticals Shire. Vpriv (velaglucerase): European public assessment report. London: European Medicines Agency; 2010."},{"key":"387_CR11","volume-title":"Cerezyme (imiglucerase): European public assessment report","author":"Genzyme Europe","year":"1997","unstructured":"Europe Genzyme. Cerezyme (imiglucerase): European public assessment report. London: European Medicines Agency; 1997."},{"issue":"Suppl 1","key":"387_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0025-7753(11)70019-7","volume":"137","author":"P Giraldo","year":"2011","unstructured":"Giraldo P. Guidelines for type 1 Gaucher\u2019s disease. Med Clin (Barc). 2011;137(Suppl 1):55\u201360.","journal-title":"Med Clin (Barc)"},{"issue":"6","key":"387_CR13","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A. How I treat Gaucher disease. Blood. 2011;118(6):1463\u201371.","journal-title":"Blood"},{"issue":"3","key":"387_CR14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood-2006-03-010801","volume":"108","author":"A Zimran","year":"2006","unstructured":"Zimran A, Elstein D, Beutler E. Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease. Blood. 2006;108(3):802\u20133.","journal-title":"Blood"},{"issue":"23","key":"387_CR15","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJM199212033272304","volume":"327","author":"ML Figueroa","year":"1992","unstructured":"Figueroa ML, et al. A less costly regimen of alglucerase to treat Gaucher\u2019s disease. N Engl J Med. 1992;327(23):1632\u20136.","journal-title":"N Engl J Med"},{"issue":"8974","key":"387_CR16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(95)91422-6","volume":"346","author":"E Beutler","year":"1995","unstructured":"Beutler E. Treatment regimens in Gaucher\u2019s disease. Lancet. 1995;346(8974):581\u20132.","journal-title":"Lancet"},{"issue":"4","key":"387_CR17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2008.12.015","volume":"96","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4\u00a0weeks versus every 2\u00a0weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Mol Genet Metab. 2009;96(4):164\u201370.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"387_CR18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","volume":"88","author":"H Ben Turkia","year":"2013","unstructured":"Ben Turkia H, et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol. 2013;88(3):179\u201384.","journal-title":"Am J Hematol"},{"issue":"1","key":"387_CR19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcmd.2011.09.009","volume":"48","author":"D Elstein","year":"2012","unstructured":"Elstein D, et al. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early access program results from Jerusalem. Blood Cells Mol Dis. 2012;48(1):45\u201350.","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"387_CR20","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3324\/haematol.2011.059071","volume":"97","author":"L Dussen van","year":"2012","unstructured":"van Dussen L, et al. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes. Haematologica. 2012;97(12):1850\u20134.","journal-title":"Haematologica"},{"issue":"1","key":"387_CR21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","volume":"39","author":"A Zimran","year":"2007","unstructured":"Zimran A, et al. A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol Dis. 2007;39(1):115\u20138.","journal-title":"Blood Cells Mol Dis"},{"issue":"9","key":"387_CR22","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood.V93.9.2807","volume":"93","author":"B Friedman","year":"1999","unstructured":"Friedman B, et al. A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Blood. 1999;93(9):2807\u201316.","journal-title":"Blood."},{"issue":"Suppl 1","key":"387_CR23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0025-7753(11)70014-8","volume":"137","author":"M Pocovi","year":"2011","unstructured":"Pocovi M. Molecular basis of treatment in Gaucher\u2019s disease. Med Clin (Barc). 2011;137(Suppl 1):32\u20138.","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"387_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI112262","volume":"77","author":"S Kornfeld","year":"1986","unstructured":"Kornfeld S. Trafficking of lysosomal enzymes in normal and disease states. J Clin Invest. 1986;77(1):1\u20136.","journal-title":"J Clin Invest"},{"issue":"1","key":"387_CR25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","volume":"20","author":"B Brumshtein","year":"2010","unstructured":"Brumshtein B, et al. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology. 2010;20(1):24\u201332.","journal-title":"Glycobiology"},{"key":"387_CR26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jpba.2013.12.027","volume":"91","author":"EG Colomer","year":"2014","unstructured":"Colomer EG, et al. Development and application to clinical practice of a validated HPLC method for the analysis of beta-glucocerebrosidase in Gaucher disease. J Pharm Biomed Anal. 2014;91:123.","journal-title":"J Pharm Biomed Anal"},{"key":"387_CR27","unstructured":"Committee for Medicinal Products for Human Use. Assessment report. Elelyso: taliglucerase alfa. London: European Medicines Agency; 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002250\/WC500135112.pdf . Accessed 14 Mar 2016."},{"issue":"3","key":"387_CR28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1615\/CritRevOncog.2013004503","volume":"18","author":"MK Pandey","year":"2013","unstructured":"Pandey MK, Grabowski GA. Immunological cells and functions in Gaucher disease. Crit Rev Oncog. 2013;18(3):197\u2013220.","journal-title":"Crit Rev Oncog"},{"issue":"4","key":"387_CR29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/hmg\/ddp523","volume":"19","author":"J Blanz","year":"2010","unstructured":"Blanz J, et al. Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase. Hum Mol Genet. 2010;19(4):563\u201372.","journal-title":"Hum Mol Genet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0387-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0387-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T18:53:21Z","timestamp":1600455201000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0387-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0387-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]}}}